{"id":"mycophenylate-mofetil","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)"},{"rate":"20-30","effect":"Leukopenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"20-30","effect":"Infection"},{"rate":"10-20","effect":"Headache"},{"rate":"5-10","effect":"Tremor"},{"rate":"10-20","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MMF is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, the predominant form in activated lymphocytes. This blocks guanosine nucleotide synthesis required for lymphocyte DNA replication, thereby suppressing T cell and B cell proliferation while having minimal effects on other cell types. It is used as an immunosuppressant to prevent organ transplant rejection and in autoimmune conditions.","oneSentence":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:17.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ transplant rejection (renal, cardiac, hepatic)"},{"name":"Autoimmune conditions including lupus nephritis and other systemic autoimmune diseases"}]},"trialDetails":[{"nctId":"NCT01962636","phase":"NA","title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-12","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia","enrollment":200},{"nctId":"NCT03198689","phase":"PHASE2","title":"Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-07","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":11},{"nctId":"NCT01095172","phase":"PHASE4","title":"RituxiMab INDuction in Renal Transplantation","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2010-11","conditions":"Function of Renal Transplant","enrollment":100},{"nctId":"NCT00383448","phase":"PHASE2","title":"HSCT for High Risk Inherited Inborn Errors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-09","conditions":"Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy","enrollment":38},{"nctId":"NCT01566656","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-03-02","conditions":"Haemato-lymphoid Malignancies or Syndromes in Whom Allogeneic Stem Cell Transplantation is Warranted","enrollment":15},{"nctId":"NCT00186628","phase":"PHASE2","title":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","status":"COMPLETED","sponsor":"Stanford University","startDate":"2005-06","conditions":"Leukemia, Mast-Cell, Mantle-cell Lymphoma","enrollment":36},{"nctId":"NCT00143559","phase":"PHASE2","title":"Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-08","conditions":"Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":17}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE RESPIRATORY FAILURE"},{"count":1,"reaction":"CANDIDIASIS"},{"count":1,"reaction":"CUSHING^S SYNDROME"},{"count":1,"reaction":"DERMATITIS EXFOLIATIVE"},{"count":1,"reaction":"DRY THROAT"},{"count":1,"reaction":"DYSPHONIA"},{"count":1,"reaction":"HYPOTENSION"},{"count":1,"reaction":"MEDICATION ERROR"},{"count":1,"reaction":"MYOSITIS"},{"count":1,"reaction":"OFF LABEL USE"}],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MMF","MMF, Cellcept","CellCept"],"phase":"marketed","status":"active","brandName":"Mycophenylate mofetil","genericName":"Mycophenylate mofetil","companyName":"Masonic Cancer Center, University of Minnesota","companyId":"masonic-cancer-center-university-of-minnesota","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection. Used for Prevention of organ transplant rejection (renal, cardiac, hepatic), Autoimmune conditions including lupus nephritis and other systemic autoimmune diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}